Compare · MDLN vs PAVM
MDLN vs PAVM
Side-by-side comparison of Medline Inc. (MDLN) and PAVmed Inc. (PAVM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PAVM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.04B, about 1088.5x PAVM ($41.4M).
- Over the past year, MDLN is down 16.0% and PAVM is down 64.0% - MDLN leads by 48.1 points.
- MDLN has been more active in the news (12 items in the past 4 weeks vs 7 for PAVM).
- MDLN has more recent analyst coverage (25 ratings vs 0 for PAVM).
- Company
- Medline Inc.
- PAVmed Inc.
- Price
- $34.25+5.09%
- $5.15-2.92%
- Market cap
- $45.04B
- $41.4M
- 1M return
- -9.02%
- +12.32%
- 1Y return
- -15.95%
- -64.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 0
PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest PAVM
- PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.
- SEC Form 10-Q filed by PAVmed Inc.
- Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
- Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
- Lucid Diagnostics to Participate in Upcoming Investor Conferences
- PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
- Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
- SEC Form S-8 filed by PAVmed Inc.